Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

18-FDG Tumour Metabolism Changes in PDL1 Superior to 50% Stage III/IV Non Small Cell Lung Cancer During First Line Treatment With Pembrolizumab

NCT03832348 is registered in ClinicalTrials.gov with Centre Henri Becquerel as lead sponsor.

NCT NCT03832348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03832348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
18-FDG Tumour Metabolism Changes in PDL1 Superior to 50% Stage III/IV Non Small Cell Lung Cancer During First Line Treatment With Pembrolizumab
Lead sponsor
Centre Henri Becquerel
Phase
Not applicable
Overall status
Completed
Start date
June 17, 2019
Completion date
July 3, 2024
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer